Ovoca Bio plc
("Ovoca" or the "Company")
Notice of AGM
Dublin, Ireland, October 6, 2022 - Ovoca Bio, a biopharmaceutical company with a focus on women's health, announces that a Notice of Annual General Meeting ("AGM"), containing details of the resolutions to be proposed at the AGM, has been published and posted to shareholders. The Notice of AGM is also available on the Company's website at www.ovocabio.com.
The Company's 2022 AGM will be held via live conference facility on 27 October 2022 at 4 p.m. Further details in relation to shareholder participation in the meeting is detailed in the Notice of AGM. The Company acknowledges that many shareholders may not be in a position to physically attend the meeting in person and as such has decided to hold this year's AGM entirely electronically, in accordance with the provisions of section 6 of the Companies (Miscellaneous Provisions) (Covid-19) Act 2020 and has put in place a number of measures to facilitate remote participation by all shareholders, as further explained in the Notice of AGM.
It will be possible to fully participate in the meeting using the live conferencing facility provided by the Company for this purpose. Shareholders will be able to use this facility to vote and /or ask questions. Shareholders will also be able to submit questions in advance of the AGM in writing by email to the Company Secretary at info@ovocabio.com to be received no later than 4 p.m. on 25 October 2022. All correspondence should include sufficient information to identify the shareholder on the Register of Members. Questions submitted using these methods will be addressed by the Chairman at the AGM, where possible.
End
For further information:
Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)
Ivan Murphy / Daragh O'Reilly
Tel: +353 1 679 6363
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated ~4 million premenopausal women in the US alone.
The Company's lead product, Orenetide (BP-101), a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.
Ovoca Bio has been granted marketing approval in the Russian Federation and is seeking to develop the drug for major global markets - in particular the United States and Europe.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
